Denali Therapeutics Conference Call Summary Company Overview - **Company**: Denali Therapeutics (NasdaqGS:DNLI) - **Focus**: Development of medicines for neurological diseases using transferrin receptor-enabled technologies Key Points Upcoming Milestones - Denali has a **PDUFA date** set for **April 5, 2026**, for its lead program, **tividenofusp alfa (Tivi)**, aimed at treating **Hunter syndrome** [3][6] Clinical Data and Regulatory Interaction - Tivi was developed starting in **2020**, with early data showing that **4 out of 5 patients** had normalized heparan sulfate after **4 doses**, indicating the platform's effectiveness [3][4] - Denali's **BLA submission** was completed last year, and interactions with the **FDA** have been described as constructive, with no further questions on the CMC aspect [5][11] - The company is in the final stages of label discussions and post-marketing commitments [11] Competitive Landscape - Denali is aware of the recent **CRL** received by **REGENXBIO** and believes its own dataset, which includes **47 patients** treated for up to **4-5 years**, positions it strongly for approval [18][19] - Denali's data shows normalization of heparan sulfate and neurodegeneration biomarkers (NfL), which are critical for demonstrating clinical benefit [18][19] Comparison with Standard of Care - The current standard of care for Hunter syndrome is **idursulfase**, which has been in use for nearly **20 years**. Denali's Tivi is engineered to cross the blood-brain barrier, potentially benefiting the **70%** of patients with severe neurological deficits [32][33] - Data indicates that patients switching from idursulfase to Tivi show improved biomarker outcomes, supporting a **switch strategy** for physicians [41][42] Commercial Strategy - Denali has built its field team and engaged with payers and centers of excellence to prepare for the launch of Tivi [35][36] - The company expects strong uptake among newly diagnosed patients and those with severe neurological manifestations [36] Genetic Testing and Newborn Screening - Genetic testing is required for an official diagnosis of Hunter syndrome, and **13 states** in the U.S. have adopted newborn screening, which is expected to increase with the approval of new medicines [46][52] Financial Strategy - Denali's deal with **Royalty Pharma** is aimed at strengthening its financial position, allowing it to fund its goals through **2028** [53] Pipeline Developments - Denali is also advancing its program for **Sanfilippo syndrome (DNL126)**, with promising data on biomarker reductions and plans for a BLA filing using CSF heparan sulfate as a surrogate endpoint [57][58] - The company is preparing to begin dosing for its **Pompe program** using the Transport Vehicle technology, which aims to improve muscle and brain biodistribution [69][70] Future Programs - Denali is developing **MAPT** and **Abeta** programs targeting Alzheimer's disease, with plans to start clinical studies soon [82][87] - The **LRRK2** program is also in progress, focusing on a kinase associated with Parkinson's disease, with enrollment nearing completion [101][107] Differentiation in Technology - Denali emphasizes its unique approach to blood-brain barrier penetration, having developed a modular system that allows for various therapeutic applications, including oligonucleotides [76][77] Conclusion - Denali Therapeutics is positioned for significant advancements in the treatment of neurological diseases, with a strong pipeline and a focus on innovative delivery mechanisms that could redefine standards of care in the field [112][113]

Denali Therapeutics Conference Call Summary Company Overview - **Company**: Denali Therapeutics (NasdaqGS:DNLI) - **Focus**: Development of therapies targeting the blood-brain barrier and neurodegenerative diseases, particularly using transferrin receptor technology for drug delivery [4][5][6] Key Points and Arguments Product Pipeline and Milestones - **Hunter Program**: First program utilizing transferrin receptor technology, showing substantial benefits in hearing, cognition, and behavior after four to five years of treatment [5] - **Tividenofusp Alpha (DNL-310)**: First BLA submitted using transferrin receptor technology, currently under review [5][10] - **Alzheimer's Portfolio**: Recent regulatory filing for an Alzheimer's medicine using oligonucleotide technology to cross the blood-brain barrier [5][6] - **ETV Franchise**: Expanding beyond Hunter and Sanfilippo, with plans for regulatory filings for Pompe disease [6] Market Opportunity - **Hunter Syndrome Market**: Benchmarking against EloPrase, which has annual sales of $650 million to $700 million, with a global distribution of one-third in the U.S., Europe, and the rest of the world [10] - **Pricing Strategy**: EloPrase costs approximately $500,000 per patient per year, and Denali anticipates a premium price for Tivi based on its clinical profile [16] Launch Strategy - **Launch Expectations**: Modest revenues expected in the first year post-launch, with a focus on patient treatment initiation as a key metric [15][20] - **Sales Force**: A small, focused sales team will be in place, leveraging existing relationships with physicians already treating Hunter syndrome patients [20][21] Sanfilippo Program - **Clinical Development**: Enrollment of 20 patients completed, with plans to file for accelerated approval based on biomarker data [22][23] - **Market Potential**: Sanfilippo is expected to have a similar market size to Hunter syndrome, with no existing standard of care, potentially allowing for flexible pricing [25] Regulatory and Manufacturing Updates - **FDA Engagement**: Ongoing discussions with the FDA regarding labeling and manufacturing issues, with a clerical error identified as a minor administrative issue [17][19] - **Manufacturing Capabilities**: Denali is transitioning to in-house manufacturing for Sanfilippo, which is expected to reduce costs [24] Other Programs - **LRRK2 Program for Parkinson's**: A phase IIb study is ongoing, with a focus on lysosomal function improvement through LRRK2 inhibition [34] - **Alzheimer's Research**: IND filed for a new oligonucleotide therapy targeting tau pathology, with a focus on achieving broad distribution in the CNS [37][38] Additional Insights - **Market Strategy**: Denali plans to leverage U.S. approval for global market access, targeting approximately 60% to two-thirds of the global market based on phase one/two data [30] - **Clinical Differentiation**: Denali's approach to FTD dementia involves a unique delivery mechanism for progranulin, contrasting with other therapies that block natural receptors [44] This summary encapsulates the key discussions and insights from the Denali Therapeutics conference call, highlighting the company's strategic direction, product pipeline, and market opportunities.